(VRNA) Verona Pharma - Ratings and Ratios
Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US9250501064
VRNA EPS (Earnings per Share)
VRNA Revenue
VRNA: Respiratory Medications, Chronic Obstructive Pulmonary Disease, Asthma
Verona Pharma PLC ADR (NASDAQ:VRNA) is a biopharmaceutical company focused on developing and commercializing therapies for respiratory diseases with significant unmet medical needs, leveraging its expertise to address conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The companys lead product, Ohtuvayre, is a groundbreaking dual inhibitor that combines bronchodilator and anti-inflammatory effects, offering a novel approach to treating these debilitating conditions.
With a strong foundation established in 2005 and headquartered in London, Verona Pharma has positioned itself as a key player in the pharmaceutical industry, particularly in the respiratory disease segment. The companys commitment to innovation is reflected in its robust pipeline and its ability to bring new treatments to market, as evidenced by the development and commercialization of Ohtuvayre.
From a technical analysis perspective, VRNAs stock has demonstrated significant growth, with its last price of $84.34 indicating a strong upward trend. The stock is trading above its 20-day and 50-day Simple Moving Averages (SMA20 and SMA50), suggesting a bullish momentum. The Average True Range (ATR) of 3.42, or 4.05%, indicates moderate volatility, and the stocks current price is near its 52-week high of $85.54, showing a strong performance over the past year.
Considering the fundamental data, Verona Pharmas market capitalization stands at $6.9 billion, underscoring its substantial presence in the market. The forward Price-to-Earnings (P/E) ratio of 476.19 suggests that investors are pricing in significant future growth, likely driven by the potential of Ohtuvayre and other pipeline assets. The negative Return on Equity (RoE) of -89.89% indicates that the company is currently not profitable, which is common for companies in the biopharmaceutical sector that are investing heavily in research and development.
Forecasting future performance based on both technical and fundamental data, VRNA is likely to continue its upward trend if it can successfully commercialize Ohtuvayre and advance its pipeline. The support levels at $73.7, $68.0, $62.4, and $54.0 provide a cushion against potential downturns, and the stocks current price near its 52-week high suggests that it has strong momentum. However, investors should be cautious of the high forward P/E ratio, which implies high expectations for future earnings growth. If the company can deliver on these expectations, particularly through the successful commercialization of its therapies, the stock could continue to perform well. Conversely, failure to meet these expectations could lead to a significant correction.
Additional Sources for VRNA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
VRNA Stock Overview
Market Cap in USD | 7,835m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2017-04-27 |
VRNA Stock Ratings
Growth Rating | 93.7 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | 483 |
Analysts | 4.7 of 5 |
Fair Price Momentum | 123.02 USD |
Fair Price DCF | - |
VRNA Dividends
Currently no dividends paidVRNA Growth Ratios
Growth Correlation 3m | 80.8% |
Growth Correlation 12m | 97.9% |
Growth Correlation 5y | 81.3% |
CAGR 5y | 77.56% |
CAGR/Max DD 5y | 1.19 |
Sharpe Ratio 12m | 1.70 |
Alpha | 474.40 |
Beta | 1.922 |
Volatility | 53.12% |
Current Volume | 750.5k |
Average Volume 20d | 1272.2k |
As of June 17, 2025, the stock is trading at USD 92.20 with a total of 750,498 shares traded.
Over the past week, the price has changed by +8.93%, over one month by +32.60%, over three months by +38.52% and over the past year by +453.42%.
Yes. Based on ValueRay´s Analyses, Verona Pharma (NASDAQ:VRNA) is currently (June 2025) a good stock to buy. It has a ValueRay Growth Rating of 93.69 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRNA is around 123.02 USD . This means that VRNA is currently undervalued and has a potential upside of +33.43% (Margin of Safety).
Verona Pharma has received a consensus analysts rating of 4.70. Therefor, it is recommend to buy VRNA.
- Strong Buy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, VRNA Verona Pharma will be worth about 147.6 in June 2026. The stock is currently trading at 92.20. This means that the stock has a potential upside of +60.12%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 97.1 | 5.3% |
Analysts Target Price | 97.1 | 5.3% |
ValueRay Target Price | 147.6 | 60.1% |